

#### **Background**

- Most patients with NMDs develop respiratory complications and/or failure due to muscle weakness, and tends to worsen with progressing disease.
- Early recognition of patient risk for pulmonary complications and integration of a pulmonologist into a coordinated multidisciplinary care can optimize outcomes
- This document highlights key points from an MDA webinar with a pulmonologist with expertise caring for patients with NMD. View the companion webinar here

#### **Respiratory Involvement in NMD**

#### Respiratory failure1

- · Hypoventilation leading to poor gas exchange
- Increasing blood carbon dioxide tension (PaCO<sub>2</sub>)
  - Initially during sleep and progressing to night and day

# NMDs with unavoidable

- occurrence of respiratory failure<sup>4</sup>
- DMD
- ALS
- · Some muscular dystrophies
- Some myofibrillar myopathies

#### Acute<sup>2</sup>

Sudden loss of lung function leading to inadequate gas exchange, arterial oxygen tension <60 mm Hg, normal or low arterial  $\rm CO_2$  tension, or increased arterial  $\rm CO_2$  tension >50 mm Hg

#### Chronic<sup>3</sup>

Failure of the inspiratory respiratory muscles to continue normal ventilation and maintain normal arterial PaCO<sub>2</sub>

# NMDs with **frequent** occurrence of respiratory failure<sup>4</sup>


- SMA2
- DM1
- GBS
- MC
- Some congenital muscular dvstrophies
- Some limb-girdle muscular dystrophies
- Some congenital myopathies
- Congenital myasthenic syndromes

ALS, amyotrophic lateral sclerosis; DM1, myotonic dystrophy type 1; DMD, Duchenne muscular dystrophy; GBS, Guillain-Barré syndrome; MG, myasthenia gravis; NMD, neuromuscular disease; PaCO2, partial pressure of carbon dioxide; SMA2, spinal muscular atrophy type 2.

1. Toussaint M, et al. Respir Med. 2021;80:106373. 2. Elhidsi M, et al. Ro J Neurol. 2022;21(3):219-224. 3. Carmona H, et al. Annu Rev Med. 2023;74:443-455. 4. Racca F, et al. Neurol Sci. 2020;41(3):497-508.

#### Pathophysiology of Respiratory Failure in NMD

Most patients with NMDs develop respiratory complications and failure due to muscle weakness<sup>1,2c</sup>



NMD, neuromuscular disease; PEmax, maximum expiratory pressure; Plmax, maximum inspiratory pressure; VC, vital capacity. 1. Voulgaris A, et al. Pulm Med. 2019;2019:2734054. 2. Elhidsi M, et al. Ro J Neurol. 2022;21(3):219-224.



Developed with the expertise of Jeanette Brown, MD, PhD (University of Utah School of Medicine) Last Reviewed: December 2023



#### Signs and Symptoms: Impaired Respiration

Recognizing early signs and symptoms of impaired respiration can aid in timely testing and intervention1-3

# Inspiratory and expiratory muscle weakness

- Tachypnea
- · Ineffective cough
- · Paradoxical breathing



#### **Bulbar muscle weakness**

- · Difficulty while swallowing and chewing
- Impaired mouth opening can hamper pulmonary function testing



#### Spine and thorax involvement

- Thoracic deformities, such as bell-shaped chest, common in patients with SMA
- Stiffness of the chest muscles



SMA, spinal muscular atrophy.

1. Boentert M. Curr Opin Neurol. 2017;30(5):529-537. 2. Ambrosino N. Eur Respir J. 2009;34(2):444-451. 3. Davidescu L. IntechOpen. 2019. doi: 10.5772/intechopen.77173.

#### **Guidelines to Manage Lung Function in NMD**

The American College of Chest Physicians® released <u>a clinical guideline</u> on respiratory management of patients with neuromuscular weakness in 2023, covering the following topics.

#### Mouthpiece ventilation<sup>1</sup>

 With NMD progression, there is a need to extend nocturnal NIV into daytime NIV using MPV

#### Transition to home MV<sup>2</sup>

- Indicated for chronic respiratory failure with alveolar hypoventilation
- · Can be NIV or invasive

#### Sialorrhea management<sup>3</sup>

- Excessive salivation from either:
  - Increased production of saliva
  - Difficulty in saliva clearance
- Patients with NMD develop sialorrhea from bulbar dysfunction
  - Poor coordination of the tongue and palate
- Leads to poor performance with NIV

#### Airway clearance therapies<sup>4</sup>

- Mucociliary clearance and cough mechanisms may be compromised
- Respiratory physiotherapy is essential in managing airway clearance

Please see guidelines for full recommendations.

MPV, mouthpiece ventilation; MV, mechanical ventilation; NIV, noninvasive ventilation; NMD, neuromuscular disease.

1. Toussaint M. Respir Med. 2021;180:106373. 2. Park S. Acute Crit Care. 2020;35(3):131-141. 3. Sahni AS. Respir Care. 2018;63(5):601-608. 4. Chatwin M. Respir Med. 2018;136:98-110.





#### Screening & Testing of Pulmonary Function\*

# PFT is recommended for patients with NMD to assist with management decisions\*

- The following PFT parameters are recommended for spirometry as predictors of clinical outcomes:
  - Forced or slow vital capacity
  - MIP/MEP or SNIP and PCF
- For patients with NMD at risk for respiratory failure, PFT is recommended at a minimum of every 6 months<sup>†</sup>
- Clinicians should adjust the testing frequency based on the progression rate of the individual NMD

# PFT is a low-cost intervention that can be performed in an office or home-based setting

- The following criteria values are considered abnormal parameters:
  - FVC <80% predicted
  - MIP <60 cm H<sub>2</sub>O
  - MEP <40 cm H₂O</p>
  - PCF <270 L/min in individuals ≥12 years of age
- Limited data to support PFT in supine vs. erect postures

#### For symptomatic patients with NMD, having normal PFT and ONO:

- Clinicians should consider PSG to assess whether NIV is clinically indicated\*
  - Clinical indications may vary based on the patient's age and disease progression
  - PSG in adults may not be needed if PFT or ONO supports use of NIV
  - Full PSG should be considered in pediatric and adult patients with daytime tiredness, fatigue, or apneic episodes
- The use of PSG in patients with NMD requires an appropriate testing facility with ADA access, NMD protocols to address hypoventilation, equipment for NMD, and space for bedside caregivers
  - ONO or PFT may be used as alternatives to PSG to help with NIV decision-making
- No data available for frequency or timing of PSG, ONO, or home sleep testing

Not exact and have been summarized; review the publication for full recommendations Khan A, et al. Chest. 2023;164(2):394-413.

### **Other Clinical Considerations for Pulmonary Care**

 Procedures that require sedation and anesthesia put patients at increased risk for:

Respiratory failure Cardiac dysrhythmias

Congestive HF

Atelectasis

Hypoventilation

Upper airway obstructions

 Consult with anesthesia team prior to procedures for consideration of which medications to avoid and the need for NIV support during sedation, as well as post-extubation NIV following general anesthesia

- Patients should be up to date on vaccinations for respiratory viruses
- If they are admitted to the hospital, they should bring their NIV device and cough assist device with them, because the facility may not have their specific device and their device is already adjusted for them
- Patients who are hypoxic should be evaluated for hypercapnia prior to having supplemental oxygen placed because this can mask hypoventilation, leading to respiratory failure

<sup>1.</sup> Birnkrant DJ, et al. Chest. 2007;132(6):1977-1986. 2. Myotonic Dystrophy Foundation. Practical Suggestions for the Anesthetic Management of a Myotonic Dystrophy Patient. https://www.myotonic.org/sites/default/files/pages/files/MDF\_PracticalSuggestionsDM1\_Anesthesia2\_17\_21.pdf.



HF, heart failure; NIV, noninvasive ventilation.



#### Resources

The American College of Chest Physicians®: Respiratory Management of patients with neuromuscular weakness. Khan A, et al. Chest. 2023;164(2):394-413.

**Published** in the journal **CHEST**®, the guideline contains:

- 15 evidence-based recommendations
- A good practice statement
- · An ungraded consensus-based statement

#### Endorsed by:

- American Association for Respiratory Care
- American Thoracic Society
- · American Academy of Sleep Medicine
- Canadian Thoracic Society



Respiratory Management of Patients With Neuromuscular Weakness

An American College of Chest Physicians Clinical Practice Guideline and Expert Panel Report

Akram Khan, MD ♦ ⊠ • Lindsy Frazer-Green, PhD • Reshma Amin, MD • ... Loutfi S. Aboussouan, MD • Douglas McKim, MD • Peter Gay, MD • Show all authors

Published: March 13, 2023 • DOI: https://doi.org/10.1016/j.chest.2023.03.011

#### Anesthetic Management: Risks & Recommendations

Anesthetic Management of Patients with Myotonic Dystrophy – Risks & Recommendations

Quick Reference Version

Myotonic dystrophy (DM) is a genetic disorder that affects CNS, cardiac, respiratory, gastrointestinal, endocrine, and muscular systems in ways that increase the risk of anesthesia.

Anesthesia Guidelines for pre-operative, intra-operative and post-operative care of DM patients, summarized below, can be found at at https://www.myotonic.org/toolkits-publications

#### **Alert Card**





#### Network of Ventilator User Resources



#### **Emergency Alert Cards**



#### **DMD Extubation Protocol**

**DMD Anesthesia Protocol** 

Parent
Project
Muscular
Dystrophy



Access companion MDA webinar here

